Blinatumomab for CNI-Resistant/Intolerant SRNS in Children

Phase 1

Recruiting

• Conditions: CNI-resistant Steriod Resistant Nephrotic Syndrome; CNI-intolerent; Steriod Resistant Nephrotic Syndrome; Multidrug Resistant Nephrotic Syndrome
• Interventions: Drug: Blinatumomab Treatment

• Registration Number: NCT06607991
• Lead Sponsor: The Children's Hospital of Zhejiang University School of Medicine

Brief Summary

This exploratory clinical trial aims to evaluate the efficacy and safety of Blinatumomab in treating children with calcineurin inhibitor (CNI)-resistant or multidrug-resistant steroid-resistant nephrotic syndrome (SRNS). Eligible participants include pediatric patients aged 2 to 17 years who have either failed to respond to adequate CNI therapy or are resistant to at least two classes of immunosuppressants, including CNIs and biologics. A short course of low-dose Blinatumomab will be administered in an open-label, single-arm, self-controlled trial design. The study seeks to determine whether Blinatumomab can reduce proteinuria and induce clinical remission in this difficult-to-treat population, offering a potential new therapeutic option for children with limited response to conventional therapies.

Detailed Description

Nephrotic syndrome (NS) in children is characterized by excessive proteinuria, hypoalbuminemia, hyperlipidemia, and edema. Approximately 15-20% of pediatric NS cases are classified as steroid-resistant nephrotic syndrome (SRNS), a condition associated with poor prognosis and limited response to standard therapies. Calcineurin inhibitors (CNIs) are frequently used as first-line immunosuppressants in SRNS; however, a subset of patients demonstrate resistance to or intolerance of CNIs. Moreover, a proportion of patients may be refractory to multiple classes of immunosuppressive agents, including biologics, posing a significant therapeutic challenge.

This exploratory, single-center, open-label clinical trial is designed to evaluate the safety and efficacy of Blinatumomab-a bispecific T-cell engager targeting CD19-positive B cells-in pediatric patients with CNI-resistant or multidrug-resistant SRNS. Eligible participants will include children aged 2 to 17 years who have either not responded to adequate CNI therapy or have failed to achieve remission despite treatment with at least two classes of immunosuppressive agents (including CNIs and biologics).

A total of 6 patients will be enrolled and administered two short courses of low-dose Blinatumomab intravenously, each lasting 5 days. The primary efficacy outcome will be the rate of complete or partial remission of proteinuria. Secondary outcomes will include safety and tolerability assessments, changes in immunologic markers, and renal function monitoring. By selectively depleting CD19-positive B cells, Blinatumomab may modulate aberrant immune activation that underlies treatment-resistant SRNS.

This study seeks to generate preliminary data on the potential therapeutic role of Blinatumomab in this difficult-to-treat pediatric population, with the ultimate goal of identifying a novel immunomodulatory approach for SRNS patients with limited treatment options.

Study Timeline

• Study First Submitted: 2024-09-18
• Study Start: 2024-09-19
• Study First Submitted QC: 2024-09-19
• Study First Posted: 2024-09-23
• Status Verified: 2025-08
• Last Update Submitted: 2025-08-03
• Last Update Posted: 2025-08-06
• Primary Completion: 2026-09-19
• Study Completion: 2027-09-18

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 6

Inclusion Criteria

Subjects must meet all of the following criteria to be included in the study:

1.Age between 2 and 17 years, regardless of gender. 2.Meet the 2021 KDIGO definition of steroid-resistant nephrotic syndrome (SRNS), and fulfill either of the following:

1. Have received an adequate dose of calcineurin inhibitors (CNIs) for more than 6 months without achieving at least partial remission.
2. Or have contraindications to CNI use, including:

1. Significant renal impairment, defined as estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m², or presence of acute kidney injury at the time of diagnosis; 2) Renal biopsy showing prominent acute or chronic tubular injury, such as tubular atrophy or interstitial fibrosis involving more than 50% of the sampled tissue; 3) Elevated urinary markers (β2-microglobulin, α1-microglobulin, or retinol-binding protein) exceeding three times the upper limit of normal; 4) Abnormal glucose tolerance; 5) Severe uncontrolled hypertension, defined as systolic and/or diastolic blood pressure ≥ the 95th percentile + 12 mmHg for age, sex, and height, or ≥ 140/90 mmHg; 6) Concomitant use of medications known to have significant interactions with CNIs, leading to increased toxicity or reduced efficacy; 7) Known allergy or hypersensitivity to CNIs or any of their components. (3) Or have demonstrated inadequate response or disease relapse after treatment with at least two immunosuppressive agents, including CNIs and at least one of the following:

1. Conventional immunosuppressive agents: cyclophosphamide, mycophenolate mofetil, azathioprine, methotrexate, cyclosporine, tacrolimus, sirolimus, leflunomide

2. Biologic agents: abatacept, ofatumumab, obinutuzumab, rituximab Inadequate response is defined as failure to achieve complete remission after 12 months of therapy or relapse following initial response.

3. Renal biopsy performed prior to screening confirms a diagnosis of minimal change disease (MCD) or focal segmental glomerulosclerosis (FSGS).

4. The subject and/or their legal guardian must provide written informed consent, indicating understanding of the study's purpose and procedures, with the right to withdraw consent at any time without affecting the subject's future medical care.

Exclusion Criteria

Subjects who meet any of the following criteria will be excluded from the study:

1. eGFR &lt; 60 mL/min/1.73 m² (using the modified Bedside Schwartz formula);
2. Stroke or seizure within 6 months prior to screening, or other active central nervous system disorders;
3. Genetic nephropathy confirmed by genetic testing;
4. Renal biopsy confirming IgA nephropathy, membranous nephropathy, or membranoproliferative glomerulonephritis;
5. Severe congenital heart disease or history of acute myocardial infarction within 6 months, or severe arrhythmias (e.g., frequent multifocal ventricular or supraventricular tachycardia, ventricular tachycardia), or moderate to large pericardial effusion, severe myocarditis, or unstable vital signs requiring vasopressors to maintain blood pressure;
6. Positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with hepatitis B virus (HBV) DNA levels above the normal range; positive for hepatitis C virus (HCV) antibodies with HCV RNA levels above the normal range; or positive for human immunodeficiency virus (HIV) antibodies, syphilis, or cytomegalovirus (CMV) DNA;
7. Abnormal laboratory values prior to screening: moderate to severe neutropenia (≤1.0×10⁹/L); moderate to severe anemia (hemoglobin ≤90 g/L); thrombocytopenia (≤75×10⁹/L); or liver dysfunction (ALT, AST, or bilirubin greater than 2.5 times the upper limit of normal and persisting for 2 weeks);
8. Subjects with tumors or other life-threatening diseases prior to screening;
9. Positive blood pregnancy test;
10. Participation in other clinical trials within 1 month prior to enrollment;
11. Received rituximab or cyclophosphamide therapy within the past 3 months;
12. Any other condition deemed by the investigator to be unsuitable for participation;
13. Vaccination with live vaccines within 4 weeks prior to screening.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Blinatumomab Treatment	Blinatumomab Treatment	-

Primary Outcome Measures

Name	Time	Method
Effectiveness and safety of Blinatumomab	with 24 weeks of Blinatumomab treatment	Effectiveness: The primary endpoint is the proportion of patients achieving complete or partial remission within 24 weeks of treatment. Complete remission is defined as a urinary protein/creatinine ratio (UPCR) ≤ 200 mg/g for three consecutive days, while partial remission is defined as a ≥ 50% reduction in proteinuria from baseline with a UPCR between 200 and 2000 mg/g.; Safety: Adverse events (AEs) and serious adverse events (SAEs) will be monitored and classified according to the CTCAE v5.0. This includes events such as cytokine release syndrome, fever, headache, and potential neurotoxicity.

Secondary Outcome Measures

Name	Time	Method
long-term efficacy of Blinatumomab and Immunological Markers	with 52 weeks of Blinatumomab	Secondary Outcome Measures: Long-term Efficacy: Maintenance of remission at 52 weeks will be evaluated, along with the time to remission and the duration of remission.; Immunological Markers: Changes in CD19+ B cell counts, particularly depletion and subsequent recovery of B cell populations, will be monitored.; Recurrence of Disease: The time to first relapse and the proportion of patients who relapse during the 52week follow-up period will be analyzed.

Trial Locations

Locations (1)

Children&#39;s Hospital, Zhejiang University School of Medicine; 🇨🇳 Hangzhou, Zhejiang, China